IFNA1 and COVID-19: The office of National Health Commission of the People’s Republic of China, and the National Administration Bureau of Traditional Chinese Medicine have jointly issued different versions of the “Guidelines for diagnosis and treatment of novel coronavirus pneumonia”, in which LPV/r, IFNα, and RBV are recommended for on-trial use in patients with COVID-19.